An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Umbrella Labs announced it’s offering three research-only compounds — retatrutide, MK-677, and RAD-140 — in its 2025 catalog. The announcement says these will be sold for laboratory research, not for people to use, and that Umbrella updated how the compounds are made and the paperwork that comes with them. The company frames this as an expansion of options for scientists doing preclinical studies. Retatrutide is a newer experimental peptide being studied for weight loss. It’s designed to mimic certain hormones that affect appetite and metabolism. MK-677 (also called ibutamoren) is not a peptide but a small molecule that stimulates growth-hormone release. RAD-140 (also called testolone) is a selective androgen receptor modulator (SARM), which acts on the same body systems as testosterone but in a more targeted way in lab models. None of these are approved as over-the-counter medicines for general use; they’re tools researchers use to study how bodies respond. What the announcement actually is: it’s a supplier telling labs they can buy these compounds for research and that the supplier has changed formulations and is providing more documentation (like purity tests, stability data, and handling instructions). This is not a clinical trial result, nor does it report new safety or effectiveness data in humans. The update affects availability and transparency for researchers, not new medical claims. If you’re not a researcher, this isn’t evidence that any of these substances are safe or effective for treating conditions. Why this matters: better access and clearer documentation can speed up early-stage research. Labs that study metabolism, muscle biology, aging, or hormone systems may be able to run cleaner experiments because they’ll get compounds with more consistent quality information. For the broader public, the practical impact is indirect: improved preclinical research can eventually lead to better clinical trials and treatments, but that’s a long process and not guaranteed. Caveats and risks: these products are sold for laboratory research only and are not regulated as medicines for people. That means they haven’t passed the safety and efficacy checks regulators require for prescription drugs. MK-677 and RAD-140 have been used off-label by some individuals, but doing so carries risks like hormone disruption, unknown long-term effects, and potential legal or health consequences. Retatrutide is still experimental; human safety and long-term effects aren’t established. If you see these names in online forums or shops, be cautious — lab-grade availability doesn’t equal approved or safe use in people. Bottom line: Umbrella Labs is making these experimental compounds easier for scientists to buy and study, with better paperwork, but this announcement is about research supply and not about proven treatments for people.
Source: Yahoo Finance